• Affiliate Professor, Global Health

Fred Hutchinson Cancer Research Center
1100 Fairview Ave N
E5-110
Seattle, WA 98109
United States

Phone Number: 
206-667-7464
Fax: 
206-667-7767
Select from the following:
Biography 

Our Group investigates the development of protective antibody responses during viral infections, with emphasis on HIV-1 and SARS-CoV-2, by employing diverse immunological, cellular and molecular high-throughput platforms. Immunogens to target specific B cell lineages are designed using structural and modeling approaches and the immune responses they elicit are characterized in detail.
https://research.fhcrc.org/stamatatos/en.html 

Education 
  • PhD (McGill University (Canada))
  • MS (University of Paris VI (France))
  • BS (University of Paris (France))
Country Affiliations 
Languages 
  • French
  • Greek
Health Topics 
  • COVID-19
  • HIV/AIDS
  • Host-Pathogen Interactions
  • Immunizations
  • Infectious Diseases
Pathobiology research areas 
Publications 

Parks, K.R., A. J. MacCamy, J. Trichka, M. Gray, C. Weidle, A. Borst, A. Khechaduri, B. Takushi, P. Agrawal, J. Guenaga, R. T. Wyatt, R. Coler, C. LaBranche, D. C. Montefiori, D. Veesler, M. Pancera, A. McGuire and L. Stamatatos. 2019. Overcoming steric restrictions of VRC01 HIV-1 neutralizing antibodies through immunization. Cell Reports. 29; 3060-3072.

Seydoux, E., L. J. Homad, A. J. MacCamy, K. R. Parks, N. K. Hurlburt, M. F. Jennewein, N. R. Akins, A. B. Stuart, Y-H. Wan,  J. Feng, R. E. Whaley, S. Singh, M. Boeckh, K. W. Cohen, M. J. McElrath, J. A. Englund, H. Y. Chu, M. Pancera, A. T. McGuire and L. Stamatatos. 2020. Analysis of a SARS-CoV-2 infected individual reveals development of potent neutralizing antibodies with limited somatic mutation. Immunity. 53; 98-105.

Lin, Y. -R., K. R. Parks, C. Weidle, A. S. Naidu, A. Khechaduri, A. Riker, B. Takushi, J.-H. Chun, A. Stuart, P. Agrawal, M. Gray, M. Pancera, P.-S. Huang and L. Stamatatos. 2020. HIV-1 VRC01 germline-targeting immunogens select distinct epitope-specific B cell receptors. Immunity. 53; 840-851.

Stamatatos, L., J. Czartoski, Y-H. Wan, L. J. Homad, V. Rubin, H. Glantz, M. Neradilek, E. Seydoux, M. F. Jennewein,  A. J. MacCamy, J. Feng, G. Mize, S. C. De Rosa,  A. Finzi, M. P. Lemos, K. W. Cohen, Z. Moodie,  M. J. McElrath, A. T. McGuire. mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection. 2021. Science. 372; 1413–1418, eabg9175.

Jennewein, M.F., A. J. MacCamy, N. R. Akins, J. Feng, L. J. Homad, N. K. Hurlburt, E. Seydoux, Y.-H. Wan, A. B. Stuart, V. V. Edara, K. Floyd, A. Vanderheiden, J. R. Mascola, N. Doria-Rose, L. Wang, E. S. Yang,  H. Y. Chu, J. L. Torres, G. Ozorowski, A. B. Ward, R. E. Whaley, K. W. Cohen, M. Pancera, M. J. McElrath, J. A. Englund, A. Finzi, M. S. Suthar, A. T. McGuire, L. Stamatatos. 2021. Isolation and Characterization of Cross-Neutralizing Coronavirus Antibodies from COVID-19+ Subjects. Cell Reports. 36; 109353